Compound: Semagacestat
SMILES: O=C1N(CCc2c([C@@H]1NC(=O)[C@@H](NC(=O)[C@@H](O)C(C)C)C)cccc2)C
InChIKey: PKXWXXPNHIWQHW-RCBQFDQVSA-N
Synonyms: Semagacestat, 425386-60-3, LY450139, LY-450139, LY 450139, 3YN0602W4W, DTXSID10235740, (2S)-2-Hydroxy-3-methyl-N-((2S)-1-(((1S)-3-methyl-2-oxo-2,3,4,5-tetrahydro-1H-3-benzazepin-1-yl)amino)-1-oxopropan-2-yl)butanamide, semagacestatum, (2S)-2-hydroxy-3-methyl-N-((2S)-1-(((1S)-3-methyl-2-oxo-4,5-dihydro-1H-3-benzazepin-1-yl)amino)-1-oxopropan-2-yl)butanamide, (2S)-2-hydroxy-3-methyl-N-[(2S)-1-[[(1S)-3-methyl-2-oxo-4,5-dihydro-1H-3-benzazepin-1-yl]amino]-1-oxopropan-2-yl]butanamide, (2S)-2-HYDROXY-3-METHYL-N-[(2S)-1-{[(1S)-3-METHYL-2-OXO-2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPIN-1-YL]AMINO}-1-OXOPROPAN-2-YL]BUTANAMIDE, RefChem:931602, DTXCID40158231, Semagacestat (LY450139), 866488-53-1, (S)-2-hydroxy-3-methyl-N-((S)-1-((S)-3-methyl-2-oxo-2,3,4,5-tetrahydro-1H-benzo[d]azepin-1-ylamino)-1-oxopropan-2-yl)butanamide, MFCD09970409, (2S)-2-hydroxy-3-methyl-N-[(2S)-1-[[(5S)-3-methyl-4-oxo-2,5-dihydro-1H-3-benzazepin-5-yl]amino]-1-oxopropan-2-yl]butanamide, (S)-2-Hydroxy-3-methyl-N-((S)-1-(((S)-3-methyl-2-oxo-2,3,4,5-tetrahydro-1H-benzo[d]azepin-1-yl)amino)-1-oxopropan-2-yl)butanamide, (2S)-2-hydroxy-3-methyl-N-[(1S)-1-methyl-2-oxo-2-[[(1S)-2,3,4,5-tetrahydro-3-methyl-2-oxo-1H-3-benzazepin-1-yl]amino]ethyl]-butanamide, Butanamide, 2-hydroxy-3-methyl-N-((1S)-1-methyl-2-oxo-2-(((1S)-2,3,4,5-tetrahydro-3- methyl-2-oxo-1H-3-benzazepin-1-yl)amino)ethyl)-, (2S)-, Semagacestat [USAN], Semagacestat [USAN:INN], Semagacestat?, UNII-3YN0602W4W, SEMAGACESTAT [MI], Semagacestat (USAN/INN), SEMAGACESTAT [INN], Semagacestat; LY450139, (2S)-2-hydroxy-3-methyl-N-[(1S)-1-methyl-2-[[(5S)-3-methyl-4-oxo-2,5-dihydro-1H-3-benzazepin-5-yl]amino]-2-oxo-ethyl]butanamide, MLS006010180, SCHEMBL417581, SEMAGACESTAT [WHO-DD], CHEMBL520733, GTPL6978, orb1301052, SCHEMBL29353755, BDBM28944, CHEBI:131158, PKXWXXPNHIWQHW-RCBQFDQVSA-N, HMS3884G21, EX-A2257, NSC755982, s1594, AKOS015924574, CCG-268180, CS-0292, DB12463, EX-1762, FS34135, NSC-755982, NCGC00346556-01, NCGC00346556-06, NCGC00346556-07, (2S)-2-Hydroxy-3-methyl-N-[(2S)-1-{[(1S)-3-methyl-2-oxo-2,3,4,5-tetrahydro-1H-3-benzazepin-1-yl]amino}-1-oxopropan-2-yl]butanamid, AC-24396, AS-42018, HY-10009, SMR004701288, NS00069725, D09377, LY450139, >=98% (HPLC), Q426010, (2S)-2-HYDROXY-3-METHYL-N-((2S)-1-(((1S)-3-METHYL-2-OXO-2,3,4,5-TETRAHYDRO-1H-3- BENZAZEPIN-1-YL)AMINO)-1-OXOPROPAN-2-YL)BUTANAMIDE, (2S)-2-hydroxy-3-methyl-N-[(1S)-1-{[(1S)-3-methyl-2-oxo-2,3,4,5-tetrahydro-1H-3-benzazepin-1-yl]carbamoyl}ethyl]butanamide, (2S)-2-hydroxy-3-methyl-N-[(1S)-1-{[(1S)-3-methyl-2-oxo-4,5-dihydro-1H-3-benzazepin-1-yl]carbamoyl}ethyl]butanamide, (N)-((S)-2-HYDROXY-3-METHYL-BUTYRYL)-1-(L-ALANINYL)-(S)-1-AMINO-3-METHYL-2,3,4,5- TETRAHYDRO-1H-3-BENZAZEPIN-2-ONE, (N)-((S)-2-Hydroxy-3-methyl-butyryl)-1-(L-alaninyl)-(S)-1-amino-3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepin-2-one, BUTANAMIDE, 2-HYDROXY-3-METHYL-N-((1S)-1-METHYL-2-OXO-2-(((1S)-2,3,4,5-TETRAHYDRO-3-METHYL-2-OXO-1H-3-BENZAZEPIN-1-YL)AMINO)ETHYL)-, (2S)-, ESF, N(SUP 2)-((2S)-2-HYDROXY-3-METHYLBUTANOYL)-N(SUP 1)-((1S)-3-METHYL-2-OXO-2,3,4,5-TETRAHYDRO-1H-3- BENZAZEPIN-1-YL)-L-ALANINAMIDE, N2-((2S)-2-(3,5-Difluorophenyl)-2-hydroxyethanoyl)-N1-((7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-L-laninamide, N2-((2S)-2-Hydroxy-3-methylbutanoyl)-N1-((1S)-3-methyl-2-oxo-2,3,4,5-tetrahydro-1H-3-benzazepin-1-yl)-L-alaninamide
Theoretical properties:
molecular_formula: C19H27N3O4
molecular_weight: 361.4 g/mol
exact_mass: 361.20015635 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 3
hydrogen_bond_acceptor_count: 4
rotatable_bond_count: 5
heavy_atom_count: 26
topological_polar_surface_area: 98.7 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
Descriptions:
pubchem: (2S)-2-hydroxy-3-methyl-N-[(2S)-1-[[(5S)-3-methyl-4-oxo-2,5-dihydro-1H-3-benzazepin-5-yl]amino]-1-oxopropan-2-yl]butanamide is a peptide.
chembl: SEMAGACESTAT is a small molecule listed in the ChEMBL database and has reached clinical trial phase 3.0.
wikipedia: Semagacestat (LY-450139) was a candidate drug for a causal therapy against Alzheimer's disease. It was originally developed by Eli Lilly and Elan, and clinical trials were conducted by Eli Lilly. Phase III trials included over 3000 patients, but in August 2010, a disappointing interim analysis, in which semagacestat performed worse than the placebo, led to the trials being stopped.